Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor ‐2 inhibitor

This article is protected by copyright. All rights reserved.

Source: Cancer Science - February 1, 2018 Category: Cancer & Oncology Authors: Chengying Xie, Xiaozhe Wan, Haitian Quan, Mingyue Zheng, Li Fu, Yun Li, Liguang Lou Tags: Original Article Source Type: research